E-ISSN: 2587-0831 ISSN: 2587-0831
IN VITRO BROMODEOXYURIDINE LABELING INDEX : PROGNOSTIC ROLE IN EARLY STAGE BREAST CANCER
PDF
Cite
Share
Request
Original Article
VOLUME: 2 ISSUE: 3
P: 118-121
July 2006

IN VITRO BROMODEOXYURIDINE LABELING INDEX : PROGNOSTIC ROLE IN EARLY STAGE BREAST CANCER

Eur J Breast Health 2006;2(3):118-121
Ersin Selçuk Ünal 1
Beyza Özçınar 1
Vahit Özmen 2
Ayhan Bilir 1
Abdullah İğci 1
Mahmut Müslümanoğlu 1
Mustafa Keçer 1
Mesut Parlak 1
1. İstanbul Üniversitesi İstanbul Tıp Fakültesi, Genel Cerrahi, İstanbul, Türkiye
2. İstanbul Üniversitesi İstanbul Tıp Fakültesi, Histoloji ve embriyoloji, İstanbul, Türkiye
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

AIM:

Various putative prognostic factors were studied in early breast cancer to evaluate local and systemic recurrence rates and make a decision for adjuvant treatments. In this study, the prognostic value of bromodeoxyuridine labeling index (BrdU LI) has been investigated in patients with early breast cancer and compared with other established clinical and biological factors.

PATIENTS AND METHODS:

After a staging work-up, the BrdU LI has been prospectively analysed in primary tumor fragments obtained from 81 consecutive patients with early breast cancer.

RESULTS:

The mean and median BrdU LI values for the whole group of patients were 6.22% and 5.18% (range: 0-27.33), respectively. Further analysis revealed that the BrdU LI rate was significantly higher in patients who had local recurrence (p= 0.026), or systemic metastases (p= 0.004).

CONCLUSION:

Our results suggest that the BrdU LI might be used as a prognostic marker to identify of patients at higher risk of relapse and to select the most appropriate adjuvant treatment for an individual patient.